Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Takeda Pharma Ups Commitment to China

publication date: Mar 23, 2011
Takeda Pharma of Japan has signed an agreement with China Medical City in Taizhou. The company’s China subsidiary will build facilities in CMC, including buildings for R&D, manufacturing and marketing of innovative drugs. The company candidly admits it is playing catch-up in China. “We missed the boat several times in China,” said Yasuchika Hasegawa, President of Takeda, last year. “We are trying to catch the last boat.” More details....

Stock Symbol: (TSE: 4502)     Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital